These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 11960598)

  • 1. Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance.
    Ma J; Murphy M; O'Dwyer PJ; Berman E; Reed K; Gallo JM
    Biochem Pharmacol; 2002 Apr; 63(7):1219-28. PubMed ID: 11960598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein alterations associated with temozolomide resistance in subclones of human glioblastoma cell lines.
    Sun S; Wong TS; Zhang XQ; Pu JK; Lee NP; Day PJ; Ng GK; Lui WM; Leung GK
    J Neurooncol; 2012 Mar; 107(1):89-100. PubMed ID: 21979894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FoxM1-mediated RFC5 expression promotes temozolomide resistance.
    Peng WX; Han X; Zhang CL; Ge L; Du FY; Jin J; Gong AH
    Cell Biol Toxicol; 2017 Dec; 33(6):527-537. PubMed ID: 28185110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple Pathway-Dephosphorylated ASK-1 Confers Temozolomide-Resistance to Human Glioma Cells.
    Gao K; She K; Fan J; Shao L; Ji Z
    Turk Neurosurg; 2024; 34(1):67-73. PubMed ID: 36951032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel Approach for Glioblastoma Treatment by Combining Apoptosis Inducers (TMZ, MTX, and Cytarabine) with E.V.A. (Eltanexor, Venetoclax, and A1210477) Inhibiting XPO1, Bcl-2, and Mcl-1.
    Zhao K; Braun M; Meyer L; Otte K; Raifer H; Helmprobst F; Möschl V; Pagenstecher A; Urban H; Ronellenfitsch MW; Steinbach JP; Pesek J; Watzer B; Nockher WA; Taudte RV; Neubauer A; Nimsky C; Bartsch JW; Rusch T
    Cells; 2024 Apr; 13(7):. PubMed ID: 38607071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone Methylation by Temozolomide; A Classic DNA Methylating Anticancer Drug.
    Wang T; Pickard AJ; Gallo JM
    Anticancer Res; 2016 Jul; 36(7):3289-99. PubMed ID: 27354585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A combined treatment regimen of MGMT-modified γδ T cells and temozolomide chemotherapy is effective against primary high grade gliomas.
    Lamb LS; Pereboeva L; Youngblood S; Gillespie GY; Nabors LB; Markert JM; Dasgupta A; Langford C; Spencer HT
    Sci Rep; 2021 Oct; 11(1):21133. PubMed ID: 34702850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Organotypic brain explant culture as a drug evaluation system for malignant brain tumors.
    Minami N; Maeda Y; Shibao S; Arima Y; Ohka F; Kondo Y; Maruyama K; Kusuhara M; Sasayama T; Kohmura E; Saya H; Sampetrean O
    Cancer Med; 2017 Nov; 6(11):2635-2645. PubMed ID: 28980419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Potential Nanofiber Membrane Device for Filling Surgical Residual Cavity to Prevent Glioma Recurrence and Improve Local Neural Tissue Reconstruction.
    Huang D; Lin C; Wen X; Gu S; Zhao P
    PLoS One; 2016; 11(8):e0161435. PubMed ID: 27548322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoxic microenvironment-induced exosomes confer temozolomide resistance in glioma through transfer of pyruvate kinase M2.
    Li G; Xiong Z; Li Y; Yan C; Cheng Y; Wang Y; Li J; Dai Z; Zhang D; Du W; Men C; Shi C
    Discov Oncol; 2024 Apr; 15(1):110. PubMed ID: 38598023
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Shi Y; Wu M; Liu Y; Hu L; Wu H; Xie L; Liu Z; Wu A; Chen L; Xu C
    Front Oncol; 2021; 11():769592. PubMed ID: 34976814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fabrication of pH-responsive temozolomide (TMZ)-clacked tannic acid-altered zeolite imidazole nanoframeworks (ZIF-8) enhance anticancer activity and apoptosis induction in glioma cancer cells.
    Ren C; Tu Q; He J
    J Biomater Sci Polym Ed; 2024 Sep; 35(13):1978-1998. PubMed ID: 38953298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The multidrug-resistance transporter Abcc3 protects NK cells from chemotherapy in a murine model of malignant glioma.
    Pessina S; Cantini G; Kapetis D; Cazzato E; Di Ianni N; Finocchiaro G; Pellegatta S
    Oncoimmunology; 2016 May; 5(5):e1108513. PubMed ID: 27467914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effect of Β-Arrestin2 Overexpression Regarding Viability and Temozolomide Treatment in High-Grade Glioma Cells.
    Oprita A; Staicu GA; Baloi C; Dricu A; Artene SA
    Curr Health Sci J; 2022; 48(4):407-412. PubMed ID: 37304796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TP53 to mediate immune escape in tumor microenvironment: an overview of the research progress.
    Zhu KL; Su F; Yang JR; Xiao RW; Wu RY; Cao MY; Ling XL; Zhang T
    Mol Biol Rep; 2024 Jan; 51(1):205. PubMed ID: 38270700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temozolomide in Combination With NF-κB Inhibitor Significantly Disrupts the Glioblastoma Multiforme Spheroid Formation.
    Xia H; Avci NG; Akay Y; Esquenazi Y; Schmitt LH; Tandon N; Zhu JJ; Akay M
    IEEE Open J Eng Med Biol; 2020; 1():9-16. PubMed ID: 35402955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lomustine and nimustine exert efficient antitumor effects against glioblastoma models with acquired temozolomide resistance.
    Yamamuro S; Takahashi M; Satomi K; Sasaki N; Kobayashi T; Uchida E; Kawauchi D; Nakano T; Fujii T; Narita Y; Kondo A; Wada K; Yoshino A; Ichimura K; Tomiyama A
    Cancer Sci; 2021 Nov; 112(11):4736-4747. PubMed ID: 34536314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined-therapeutic strategies synergistically potentiate glioblastoma multiforme treatment
    Yang J; Shi Z; Liu R; Wu Y; Zhang X
    Theranostics; 2020; 10(7):3223-3239. PubMed ID: 32194864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rare Stochastic Expression of O6-Methylguanine- DNA Methyltransferase (MGMT) in MGMT-Negative Melanoma Cells Determines Immediate Emergence of Drug-Resistant Populations upon Treatment with Temozolomide In Vitro and In Vivo.
    Chen TC; Chan N; Minea RO; Hartman H; Hofman FM; Schönthal AH
    Cancers (Basel); 2018 Sep; 10(10):. PubMed ID: 30274152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temozolomide resistance in glioblastoma multiforme.
    Lee SY
    Genes Dis; 2016 Sep; 3(3):198-210. PubMed ID: 30258889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.